MedinCell: SAIVE Study data to be presented at ECCMID 2023 Euronext: MEDCL April 17, 2023 April 17, 2023
MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group March 27, 2023 March 27, 2023
MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company February 23, 2023 February 23, 2023
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK) January 24, 2023 January 24, 2023
MedinCell announces the initiation of coverage of its stock by TPICAP Midcap January 5, 2023 January 5, 2023
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population January 5, 2023 January 5, 2023
MedinCell publishes its financial results for the first semester of 2022-2023 December 6, 2022 December 6, 2022
Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive November 30, 2022 November 30, 2022
Details of the financing agreement signed by MedinCell and the European Investment Bank (EIB) November 23, 2022 November 23, 2022
France : EIB and MedinCell sign a new €40 million loan agreement to support development of innovative treatments November 23, 2022 November 23, 2022
MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London November 8, 2022 November 8, 2022
